A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Inclusion Criteria:

• 18 to 70 years old at the time of signing the Informed Consent Form (ICF).

• Diagnosed as SLE/Immune-Mediated Necrotizing Myopathy (IMNM)/Neuromyelitis OpticaSpectrum Disorders (NMOSD)/Multiple Sclerosis (MS)/Myasthenia Gravis (MG) accordingto recognized diagnostic criteria for at least 6 months.

• Remains disease active or relapses after treatment with standard of care therapy forat least 8 weeks with the dose stable for more than 2 weeks; patients should havebeen treated at least two immunosuppressants (immunosuppressants ordisease-modifying drug (DMD) for MS participants).

• Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.

Exclusion Criteria:

• Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive.

• Uncontrolled active infection.

• Live vaccine injection within 4 weeks prior to signing the ICF.

• Major organ transplantation history or bone marrow/hematopoietic stem celltransplantation history.

• Severe cardiovascular diseases within the past 6 months prior to screening.

• ≥ Grade 2 bleeding within the past 30 days prior to screening, or requiringlong-term anticoagulants treatment.

• Inadequate washing time for previous treatment.

• Previously treated with CAR-T cell products or genetically modified T celltherapies.

• Pregnant or lactating women.

• Severe central nervous system diseases or pathological changes.

• Malignancy history within 5 years prior to signing the ICF.